Last updated on August 2014

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ® (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors


Brief description of study

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ® (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors

Detailed Study Description

A study to evaluate the effect of long-term treatment with Belviq® (Lorcaserin HCI) on the incidence of major adverse cardiovascular events and conversion to Type 2 Diabetes Mellitus in obese and overweight subjects with cardiovascular disease or multiple cardiovascular risk factors.

Half of the patients will be randomly assigned to receive Belviq® 10 mg twice daily and half of the patients will be assigned to a matching placebo. All patients will be on a reduced-calorie, increased physical activity program and participate in a Healthy Lifestyles Program which includes access to a nutritionist as well as online diet and exercise resources.

Clinical Study Identifier: TX139056

Contact Investigators or Research Sites near you

Start Over

Wendy Schneider, MSN, RN, CCRC

Holy Cross Jim Moran Heart and Vascular Research Institute
Coral Springs, FL USA
  Connect »